The Competition and Markets Authority (CMA) has launched an in-depth Phase 2 investigation into the proposed £14.5 billion acquisition of Cambridge-based gene-sequencing pioneer, HelixSynthetix, by the US laboratory equipment conglomerate, Apex BioSystems. The CMA expressed concern that the merger could restrict rival diagnostic laboratories' access to HelixSynthetix’s proprietary nanopore sequencing chips. This vertical integration could lead to higher costs for clinical cancer-screening developers and ultimately inflate prices for patients and national healthcare systems. This comes amid rising global demand for personalized oncology tools, sparking fears that Apex could foreclose domestic medical-tech start-ups.
Conversely, representatives for Apex BioSystems contend that the clinical validation and global scale-up of nanopore technology require vast capital reserves. They argue that only a multi-national giant can absorb the high failure rates of clinical trials and expand manufacturing fast enough to meet global preventative health targets.
Using the information in Extract C, discuss the likely concerns of the competition authorities regarding the proposed merger of the two companies.
